ESG Report 2022

Products in R&D Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited 13 Clinical trial Preclinical R&D Stage: Clinical registration Indications Diabetes Product TUL01101Tablets* Insulin Degludec / Liraglutide Diabetes , Obesity & Nonalcoholic Steatohepatitis (NASH) Osteoporosis Diabetes Eczema & Asthma Rheumatoid Arthritis Atopic Dermatitis Conjunctivitis Semaglutide Injection Hyperlipidemia SLE&other Autoimmune Disease Inflammatory diseases Atopic Dermatitis Xerophthalmia Bacterial Infection Dermatosis Erectile Dysfunction Xerophthalmia IgA Nephritis Inflammatory Bowel Disease Hyperuricemia Gout & Obesity Xerophthalmia R&D Stage GLP - 1 Oral Preparation * Novel Recombinant Urate Oxidase * Osteoporosis Monoclonal Antibody Anti - osteoporosis Peptides Anti - IL - 4R monoclonal antibody Second - generation GI Hormones * Ultra - long - acting Insulin analogue * Gastrointestinal ( GI ) Hormones * Interleukin - 2 Fusion Protein * Dual Target Hypolipidemic Drugs * TUL01101Tablets* TUL01101 Ointment* TUL12101Eye Drops* Liraglutide Injection Insulin Degludec Injection Insulin Degludec / Insulin Aspart Semaglutide Injection Olotadine Hydrochloride Eye Drops Polyvinyl Alcohol Eye Drops Moxifloxacin Eye Drops LB2311* LB2132* Mupirocin Ointment Tadalafil tablets Sodium Hyaluronate Eye Drops LB1091* LB2012* LB2023* * Class I new drug